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Dystrophin-related and -associated proteins are im-
portant in the formation and maintenance of the mam-
malian neuromuscular junction. We have characterized
mouse cDNA clones encoding isoforms of the dystro-
phin-homologous 87-kDa postsynaptic protein, dystro-
brevin. In Torpedo, the 87-kDa protein is multiply phos-
phorylated and closely associated with proteins in the
postsynaptic cytoskeleton, including the acetylcholine
receptor. In contrast to Torpedo, where only a single
transcript is seen, the mouse expresses several mRNAs
encoding different isoforms. A 6.0-kilobase transcript in
brain encodes a 78-kDa protein (dystrobrevin-1) that is
very similar to the Torpedo sequence. A second tran-
script encodes a 59-kDa protein (dystrobrevin-2) that
has a different C terminus, lacking the putative tyrosine
kinase substrate domain. In skeletal and cardiac mus-
cle, transcripts of 1.7 and 3.3/3.5 kilobases predominate
and encode additional isoforms. Alternative splicing
within the coding region and differential usage of un-
translated regions produce additional variation. Mul-
tiple dystrobrevin-immunoreactive proteins copurify
with syntrophin from mouse tissues. In skeletal muscle,
dystrobrevin immunoreactivity is restricted to the neu-
romuscular junction and sarcolemma. The occurrence
of many dystrobrevin isoforms is significant because
alternative splicing and phosphorylation often have
profound effects upon the biological activity of synaptic
proteins.
Chemical synapses in the peripheral and central nervous
systems mediate intercellular communication, controlling and
coordinating an overwhelming range of cellular processes. De-
spite their importance, comparatively little is known about the
structure and function of synapses in the brain. The majority of
our knowledge of synapse structure originates from the study
of the specific contact that occurs between a motor neuron and
a muscle fiber: the neuromuscular junction (NMJ).1 The NMJ
consists of a presynaptic nerve terminal separated from the
postsynaptic muscle cell by the synaptic cleft containing the
basal lamina. The morphology and molecular architecture of
the NMJ are critical for efficient synaptic transmission.
The formation of dense clusters of acetylcholine receptors
(AChRs) at the point of contact between the motor neuron and
muscle fiber is an early event in postsynaptic differentiation.
Of the various factors that influence AChR clustering, agrin, an
extracellular matrix protein secreted by the motor neuron,
appears to play a pivotal role (2). In addition to AChR cluster-
ing, agrin also induces the redistribution of many other
postsynaptic (3, 4) and cytoskeletal (5) proteins. These localized
cellular changes lead to the formation of microclusters of
AChRs that are subsequently developing into the macroclus-
ters characteristic of the mature synapse.
Central to the role of agrin in synaptogenesis is the cell-
surface agrin receptor. a-Dystroglycan (156-kDa dystrophin-
associated glycoprotein), a component of the dystrophin-asso-
ciated glycoprotein complex (DGC), has recently been shown to
be an agrin receptor in skeletal muscle (6–9). Extra-junction-
ally, a-dystroglycan binds to the laminin a2-chain (merosin) in
the extracellular matrix and to components of the DGC that
span the sarcolemma (10). One of these transmembrane pro-
teins, b-dystroglycan (43-kDa dystrophin-associated glycopro-
tein), binds to the cysteine-rich domain of dystrophin (11).
Since the N terminus of dystrophin binds to actin (12, 13), the
dystroglycans effectively link the cytoskeleton of the muscle
fiber to the extracellular matrix.
The immobilization of AChR clusters is thought to be accom-
plished by proteins in the junctional cytoskeleton (14). Al-
though dystrophin is present in the cytoskeleton of the NMJ
(15–17), utrophin, an autosomally encoded homologue of dys-
trophin (18), precisely colocalizes with the AChR clusters at the
crests of the junctional folds (19–21). Utrophin, like dystro-
phin, also binds to components of the DGC (22). An attractive
hypothesis is that agrin binding to a-dystroglycan at the NMJ
causes a local accumulation and reorganization of cytoskeletal
proteins and, in particular, utrophin, eventually resulting in
the immobilization of AChR clusters by a cytoskeletal scaffold.
This hypothesis is supported by evidence showing that utro-
phin is present in spontaneous clusters of AChRs (23) and
following agrin induction (7).
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In Torpedo electric organ, two proteins with molecular
masses of 87 and 58 kDa (syntrophin) are associated with
dystrophin and postsynaptic complexes. The 87-kDa protein is
a minor component of the postsynaptic membrane that copuri-
fies with the AChR in the electric organ membranes (24).
Monoclonal antibodies (mAbs) raised against this protein label
Torpedo electric organ, mammalian end plates, and, to a lesser
extent, the extrasynaptic sarcolemma (24). The 87-kDa protein
coimmunoprecipitates with dystrophin and syntrophin (25, 26).
Three mammalian syntrophin genes have been identified by
molecular cloning (27–29). The b2-form of syntrophin is highly
localized to the neuromuscular postsynaptic membrane,
whereas a-syntrophin is ostensibly located at the sarcolemma
(30).
Cloning of the Torpedo 87-kDa cDNA revealed moderate but
significant sequence similarity to the cysteine-rich and C-ter-
minal domains of the dystrophin protein family (1, 31). Similar
regions in dystrophin, utrophin, and the 87-kDa protein con-
tain the binding sites for the mammalian homologues of syn-
trophin (32–35). In Torpedo, the 87-kDa postsynaptic protein is
the product of a single 4.6-kb transcript expressed in the elec-
tric organ, in brain, and in skeletal muscle (1). While the
function of the 87-kDa protein is unresolved, a role in the
formation and stability of synapses has been proposed (1). The
87-kDa protein is also a major phosphotyrosine-containing pro-
tein in Torpedo electric organ (1). This is particularly signifi-
cant because agrin-induced AChR clustering is blocked by in-
hibitors of tyrosine kinase (14, 36, 37). In mammalian tissues,
multiple 87-kDa cross-reactive proteins copurify with syntro-
phin from many different rat tissues (26). The 87-kDa protein
may therefore have other functions in addition to its role in
synaptogenesis.
To investigate the molecular organization of utrophin- and
dystrophin-containing complexes in mouse brain and muscle,
we have cloned the murine homologue of the Torpedo 87-kDa
postsynaptic protein. In this paper, we show that there are
many different murine 87-kDa protein isoforms produced from
alternatively spliced transcripts. This is at variance with the
situation in Torpedo where only a single transcript and protein
have been described (1). Many of these 87-kDa isoforms are
associated with syntrophin in different mouse tissues. In rat
skeletal muscle, 87-kDa immunoreactivity is restricted to the
NMJ and sarcolemma. Our studies parallel the heterogeneity
and localization of the mammalian dystrophin/utrophin family
and the syntrophin family (38), all of which are potential li-
gands for the 87-kDa isoforms described herein. In deference to
the 87-kDa protein being a low molecular mass protein with
homology to dystrophin and in agreement with other research-
ers studying this protein, we have adopted the name dystro-
brevin for proteins encoded by the murine 87-kDa gene.
EXPERIMENTAL PROCEDURES
RNA Extraction and Northern Blotting—RNA was extracted from
mouse tissue or cultured cell lines following the method of Chomczynski
and Sacchi (49). mRNA was prepared from ;250 mg of total RNA using
Oligotex (QIAGEN, Inc.) following the manufacturer’s instructions.
Northern blots were prepared as described previously (50). All North-
ern blots were washed at the same stringency (2 3 SSC, 0.1% SDS at
65 °C for 30 min).
cDNA Library Construction and Screening—A cDNA library was
made from 5 mg of adult mouse brain mRNA following an adaptation of
the method of Gubler and Hoffman (51). Briefly, denatured mRNA was
reverse-transcribed in a 100-ml solution containing 150 units of avian
myeloblastosis virus reverse transcriptase, 14 mM dithiothreitol, 100
units of RNase inhibitor, 5 mg of oligo(dT)25–30, 1 mM dNTPs, and 1 3
RT1 buffer (5 3 RT1 buffer 5 250 mM Tris-HCl (pH 8.2 at 42 °C), 250
mM KCl, and 30 mM MgCl2) for 1 h at 42 °C. The second strand was
synthesized in a final volume of 400 ml by diluting the first strand
reaction with 80 ml of 5 3 RT2 buffer (100 mM Tris-HCl (pH 7.5), 500
mM KCl, 25 mM MgCl2, and 0.25 mg/ml bovine serum albumin), 10 ml of
10 mM NAD1, 20 units of Escherichia coli DNA ligase, 4 units of RNase
H, and 100 units of E. coli DNA polymerase I. The volume was adjusted
to 400 ml with diethyl pyrocarbonate-treated water, and the reaction
was incubated for 90 min at 16 °C followed by 30 min at 22 °C. The DNA
was treated with 4 units of T4 DNA polymerase (Boehringer Mannheim
Corp.) for 15 min at 37 °C and purified. BstXI/EcoRI adaptors were
ligated to the blunt-ended cDNA at room temperature for 16 h. The
adaptors and short cDNAs (,175 base pairs) were removed using
Geneclean (BIO 101, Inc.). Purified adapted cDNA was ligated into the
BstXI sites of pcDNAII (Invitrogen). The cDNA library was used to
transform electrocompetent or chemically competent E. coli XL-1Blue.
The cDNA library was plated at high density on Hybond-N membranes
(Amersham Corp.) and screened with [a-32P]dCTP-labeled probes.
RT-PCR—10 mg of denatured total RNA was converted into first
strand cDNA with 50 units of avian myeloblastosis virus reverse tran-
scriptase in a final volume of 100 ml in a solution containing 14 mM
dithiothreitol, 40 units of RNase inhibitor, 1 mg of oligo(dT)12–18, 1 mM
dNTPs, and 20 ml of 5 3 RT1 buffer for 1 h at 42 °C. 2.5 ml of a 1:10
dilution of the first strand cDNA was used in 50-ml PCR reactions,
performed under standard conditions using Taq DNA polymerase
(Perkin-Elmer).
Sequence Analysis—cDNA clones were prepared for sequencing by
making nested deletions with exonuclease III and S1 nuclease following
the manufacturer’s instructions (Erase-a-Base, Promega). Deleted plas-
mids were assessed by PCR with Sp6 and T7 vector primers. Deleted
plasmids in the correct size range were sequenced with the appropriate
vector primer with a Sequenase kit (U. S. Biochemical Corp.) following
the manufacturer’s instructions for double-stranded sequencing. Se-
quences were manually entered into a data base and assembled using
the Genetics Computer Group Version 7.3 software package.
Antibody Production—Polyclonal antibodies were prepared in rab-
bits using synthetic peptides according to standard methods. Ab 308
and Ab 433 were generated against peptides CASSREPLHPMFPDQ-
PEKPLN and CRVEHEQASQPTPEKAQQNP (corresponding to amino
acids 308–328 and 433–451 plus an amino-terminal cysteine for cou-
pling), respectively. Each antibody was affinity-purified from serum
using peptide-coupled Affi-Gel 10 (Bio-Rad) as described previously
(26).
Immunoblots—Preparations enriched for syntrophins and associated
proteins were immunoaffinity-purified from Triton X-100 extracts of
mouse tissues using mAb SYN1351 as described previously (26). Sam-
ples were resolved on 8% SDS-polyacylamide gels, transferred to Im-
mobilon-P (Millipore Corp.), and blotted (26). Blots were incubated with
mAb SYN1351 (60 pM), Ab 308 (30 nM), or Ab 433 (30 nM) followed by
appropriate horseradish peroxidase-coupled secondary antibody
(1:3000; Jackson ImmunoResearch Laboratories, Inc.). Blots were de-
veloped using enhanced chemiluminescence (Pierce) and exposed to
Bio-Max film (Eastman Kodak Co.).
Immunofluorescence—Cryosections (8 mm) of unfixed rat sternomas-
toid were labeled with Ab 433 (20 nM) followed by rhodamine-conju-
gated donkey anti-rabbit secondary antibody (Jackson ImmunoRe-
search Laboratories, Inc.) as described previously (16). Labeling was
examined in regions of NMJs identified with BODIPY-a-bungarotoxin
(1:3000; Molecular Probes, Inc.). As a control, Ab 433 was preincubated
with its corresponding peptide (100 mM) for 1 h prior to use. Labeling
with each fluorophore was photographed and processed equivalently.
RESULTS
Isolation of cDNAs Encoding the Murine Orthologue of the
Torpedo 87-kDa Postsynaptic Protein—Nucleic acid sequence
data bases were searched with the Torpedo sequence encoding
the 87-kDa postsynaptic protein. This search identified several
human expressed sequence tags that had significant similarity
to the query sequence. Oligonucleotide primers were designed
to one of the sequences, EST000891 (39), and used to amplify a
single DNA fragment from first strand cDNA made from hu-
man fetal brain and dorsal root ganglia RNAs. This amplified
cDNA was used to screen a human fetal brain cDNA library.
Two positively hybridizing clones, 87e1 (1.6 kb) and 87e3 (0.5
kb), were picked and partially sequenced. Both clones were
similar to EST000891 and the Torpedo sequence. Because 87e1
was the larger of the two clones, it was used for Northern
blotting and cDNA library screening.
Clone 87e1 was hybridized to a Northern blot of mRNAs from
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mouse brain and two cell lines. 87e1 hybridized to five tran-
scripts of 6.0, 4.3, 3.5, 3.3, and 1.7 kb in adult brain mRNA (Fig.
1). Additionally, a single 6.0-kb band was detected in the mouse
muscle cell line BC3H-1 and monkey kidney COS-7 cells (Fig.
1). No hybridization was observed to embryonic mouse brain
RNA. 87e1 was used to screen an adult mouse brain cDNA
library constructed from an aliquot of the same mRNA sample
that was used in the initial Northern blot. Two cDNA clones,
m871 (1.9 kb) and m872 (1.7 kb), were isolated from the first
screening. Both clones were entirely sequenced. The majority of
m872 and half of m871 were similar to the coding region of the
Torpedo nucleotide sequence; however, the sequence of m871
diverged from the m872 sequence at the 39-end. It was thereby
concluded that m871 and m872 were partial cDNAs from sep-
arate but related transcripts, consistent with the multiple band
pattern seen on Northern blots (Fig. 1). With this in mind, the
cDNA library was rescreened with both the m871 and m872
cDNA clones.
Ten positively hybridizing clones were isolated in the second
screening. Each clone was analyzed by restriction mapping and
end sequencing. The largest clones were placed into two
groups: those that were similar to m871 (m22 (3.2 kb) and m24
(2.8 kb)) and those that were similar to m872 (m32 (3.0 kb),
m21 (2.8 kb), and m11 (2.2 kb)) (Fig. 2). Because clones m24
and m32 appeared to extend most 59, they were entirely se-
quenced (Fig. 3, A and B).
The sequence of m24 revealed a number of interesting fea-
tures. First, m24 had no obvious similarity to the majority of
the 59-untranslated region (UTR) of the Torpedo sequence. The
homology between m24 and the Torpedo sequence starts at
nucleotide 135 of the Torpedo sequence, in the region encoding
the second in-frame methionine codon. Translation of the m24
sequence from this ATG codon predicts a protein of 78 kDa that
has 83% identity to the Torpedo protein sequence. Upstream of
this initiation codon are two in-frame stop codons, indicating
that this sequence is most likely to be the 59-UTR of m24.
Second, computer-assisted alignments of the m24-encoded pro-
tein sequence with the Torpedo sequence showed that although
there was considerable identity between the two sequences,
there was one sizable gap in the m24 sequence, encompassing
amino acids 370–400 of the Torpedo sequence (Fig. 3C). Third,
the similarity to the cysteine-rich and C-terminal domains of
dystrophin and utrophin was retained and included the repeat-
ing heptad of leucine residues predicted to form the a-helices of
coiled-coils implicated in protein-protein interactions (1, 31).
The sequence of m24 was identical to the m871 sequence
throughout the region of overlap. The sequences of m24 and
m871 39 of the TGA stop codon overlapped with the 59-end of
m22 (Fig. 2A). The other end of m22 showed significant simi-
larity to the 39-UTR of the Torpedo cDNA including the pro-
posed polyadenylation site (data not shown). The m22 cDNA is
therefore part of the 39-UTR of the same transcript from which
m24 and m871 are derived. Because the m24 and m22 cDNAs
are 2.8 and 3.2 kb, respectively, and they overlap by ;50 base
pairs, it was concluded that they are derived from the 6.0-kb
brain transcript (Fig. 1). This was confirmed by Northern blot-
ting (see below) and by RT-PCR (data not shown). We have
named the 78-kDa protein product of the 6.0-kb transcript
“dystrobrevin-1” to distinguish it from the other proteins de-
scribed in this study.
The extreme 59-end of m32 had no homology to the Torpedo
sequence or to the m24 sequence. In common with m24, the
homology to the Torpedo sequence started at nucleotide 135.
Upstream of this sequence are stop codons in every reading
frame, indicating that this sequence is not translatable and
therefore is the 59-UTR. Conceptual translation of the m32
sequence yielded a long open reading frame encoding a 59-kDa
protein. There are some significant differences between the
sequences of m32 and m24 and the Torpedo sequence. The m32
sequence diverges from m24 at amino acid 504 of the m32
sequence (Fig. 3C). A TAA stop codon occurs after 30 nucleo-
tides, resulting in a protein with a different C terminus (Fig.
3B). m32 therefore encodes a protein devoid of the tyrosine
kinase substrate domain described by Wagner et al. (1). In
common with the 59-UTRs, m32 and m24 also have different
39-UTRs. Comparison of the m24 and m32 sequences revealed
two other minor differences. m32 has an insertion of 9 nucleo-
tides that code for the tripeptide DTW. This sequence is not
present in m24 or in the Torpedo sequence (Fig. 3C). Addition-
ally, there is a single base difference between the two se-
quences, resulting in a neutral amino acid difference of Leu-
251 in m32 and Val-251 in m24. Valine is found at this position
in the Torpedo sequence (Fig. 3C). Like m24, the m32 sequence
contains a deletion of amino acids 370–400 of the Torpedo
sequence (Fig. 3C). This observation is investigated below.
The sequences of m32 and m872 39 of the stop codon are
identical. The 39-ends of m32, m21, and m11 also overlap,
suggesting a common 39-UTR in all the clones. In contrast, the
extreme 59-end of m21, within the predicted 59-UTR, differs
from the sequence of m32, although the remainder of the 59-
UTR is identical in these clones. This result indicates that the
59-UTRs of some of the dystrobrevin transcripts may be en-
coded by more than one exon. Because clones m32 and m21 are
both ;3.0 kb and their 59-UTRs are different, the correspond-
ing transcript sizes (4.3, 3.5, or 3.3 kb) cannot be directly
deduced. We have named the 59-kDa protein encoded by the
m32 cDNA clone “dystrobrevin-2.”
Alternative Splicing—Sequence analysis of other clones iso-
lated from the adult mouse brain cDNA library and of RT-PCR
products cloned from different mouse tissues revealed the pres-
ence of at least four different variants. These differences are
most likely to be the result of alternative splicing; however, it
is formally possible that this variation is the consequence of
sequence divergence between very closely related genes.
In addition to the sequence differences in the 59-UTRs of
clones m24, m32, and m21 described above, there are three
variable regions within the protein coding sequence. An extra 3
amino acids (DTW) occur at position 335 of the m32 peptide
sequence that are not present in the m24 sequence. We have
designated this site “variable region (vr) 1.”
FIG. 1.Northern blot hybridized with a cDNA encoding part of
the human dystrobrevin. 5 mg of mRNA prepared from the following
sources was hybridized with 87e1: a mouse BC3H-1 smooth muscle-like
cell line, monkey kidney COS-7 cells, embryonic mouse brain (EMB),
and adult mouse brain (AMB). The 6.0-kb full-length transcript was
present in all samples except embryonic mouse brain mRNA. Addi-
tional transcripts of 4.3, 3.5, 3.3, and 1.7 kb (represented by asterisks)
were also detected in adult mouse brain mRNA.
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A stretch of charged residues (EEELKQGTR) corresponding
to amino acids 495–503 of the m24 sequence (Fig. 3A) is re-
placed by the sequence TQG encoded by m871 (Fig. 4A). We
have designated this region “vr2.” vr2 covers the point where
the predicted C termini of the brain dystrobrevin-1 and dystro-
brevin-2 sequences diverge and is immediately adjacent to the
coiled-coil region conserved in the dystrophin-related protein
family (31). The Torpedo sequence is also similar to the 9 amino
acids at vr2 (Fig. 3C).
Computer-assisted alignment of the predicted protein se-
quences of m24 and m32 with the Torpedo peptide sequences
shows that the region encompassing amino acids 363–400 of
the Torpedo sequence is not present in the two mouse se-
quences (Fig. 3C). The mouse brain cDNA clones only have a
small additional stretch of nonhomologous sequence (FITRSM)
before the similarity with the Torpedo sequence is restored
after amino acid 400. Oligonucleotides were made that flanked
this region and were used to amplify first strand cDNA pre-
pared from various mouse tissues. Products of the predicted
size were obtained in brain cDNA; however, the products in
skeletal and cardiac muscle were ;200 base pairs larger (data
not shown). The products from both tissues were cloned and
sequenced. Sequence analysis showed that the additional se-
quence, accounting for the increased mobility of the PCR prod-
ucts in heart and muscle, was very similar to the region encod-
ing amino acids 364–399 of the Torpedo sequence, but absent
in m24 and m32. The region of similarity between the Torpedo
and mouse sequences is not continuous, but is interrupted by
two insertions of 5 and 21 amino acids in the mouse sequence
(Fig. 4B). RT-PCR showed that this region, which we have
called “vr3,” appears to be specific to skeletal and cardiac
muscle (data not shown).
Since the dystrobrevin-1 and dystrobrevin-2 transcripts dif-
fer in their 39-ends (Fig. 3, A and B) and hybridize to tran-
scripts in heart and skeletal muscle (Fig. 5, A and C), it was
important to determine whether vr3 was specific to either
transcript. RT-PCR using a forward primer in the common
coding sequence and a reverse primer in the 39-UTR of either
the dystrobrevin-1 or dystrobrevin-2 sequence only gave prod-
ucts that included the vr3 sequence. This was confirmed by
cloning and sequencing (data not shown). These data indicate
that the major dystrobrevin-encoding transcripts in heart and
skeletal muscle contain vr3 and are thus different from the
transcripts present in brain. We have named the protein that
contains the vr3 sequence and is encoded by a transcript with
the same 39-UTR as the dystrobrevin-1 transcript “dystrobre-
vin-3.” Similarly, we have named the protein that contains the
vr3 sequence but is encoded by a transcript with the same
39-UTR as the dystrobrevin-2 transcript “dystrobrevin-4.” The
organization of dystrobrevin-1, -2, -3, and -4 is summarized in
Fig. 4C.
Tissue Distribution of the Murine Dystrobrevin Tran-
scripts—In Torpedo, the 87-kDa postsynaptic protein is en-
coded by a single 4.6-kb transcript expressed in the electric
organ, in brain, and in skeletal muscle (1). Preliminary North-
ern blot analysis indicated that several transcripts in mouse
brain RNA hybridized to a cDNA clone encoding part of human
dystrobrevin (Fig. 1). Furthermore, at least two families of
cDNA clones were obtained from the adult mouse brain cDNA
library. To examine the tissue distribution of these transcripts,
Northern blots prepared from mouse tissue RNA were hybrid-
ized with different cDNA clones and subclones.
Northern blots hybridized with clone m872 (Fig. 2), encoding
the majority of dystrobrevin-2, gave a complex band pattern
(Fig. 5A). The m872 cDNA clone was chosen because it contains
coding sequence that is common to both dystrobrevin-1 and
dystrobrevin-2. In brain RNA, m872 hybridized strongly to
transcripts of 6.0, 4.3, 3.5, 3.3, 1.7, 1.2, and 0.7 kb. The hybrid-
ization pattern in the other tissues is less complex. In heart,
m872 hybridized to two transcripts of 3.3 and 1.7 kb. In skel-
etal muscle and lung, m872 hybridized predominantly to three
transcripts of 6.0, 3.5 (3.3 kb in muscle), and 1.7 kb. No strongly
hybridizing transcripts were detected in RNA from other tis-
sues. The 6.0-kb full-length transcript as well as the 4.3-, 3.5-,
3.3-, and 1.7-kb transcripts are also present in the adult mouse
brain mRNA (Fig. 1) used in the cDNA library construction.
FIG. 2. Restriction map of the murine cDNA clones predicted to encode brain dystrobrevin-1 (A) and brain dystrobrevin-2 (B). The
structure of the Torpedo transcript is shown for reference and is not meant to indicate regions of homology. hI 1 hII denotes the location of the
a-helices predicted to form the coiled-coils conserved in proteins with homology to the C terminus of dystrophin (31), and TYR in the Torpedo
87-kDa sequence denotes the tyrosine kinase substrate domain (1). The polyadenylation consensus sequence, ATTAAA, is shown in parentheses
because it is only homologous to the Torpedo sequence and may not be the true polyadenylation signal. The dashed line at the end of the
dystrobrevin-2 restriction map indicates that the entire dystrobrevin-2-encoding transcript(s) has not been cloned. B, BamHI; E, EcoRI;H,HindIII;
Sc, SacI; S, SphI; X, XhoI.
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To establish the molecular basis of this complex pattern of
transcripts, Northern blots were hybridized with cDNA sub-
clones. Using the 1.1-kb EcoRI restriction fragment fromm871,
composed of sequence unique to the dystrobrevin-1 transcript,
the major transcript detected is 6.0 kb (Fig. 5B). This transcript
is abundant in brain, but can also be detected at lower levels in
muscle and lung and very weakly in kidney. Additionally, a
weakly hybridizing 3.3-kb transcript is also detected in brain,
lung, and muscle RNAs. This confirms that the brain transcript
encoding dystrobrevin-1 is 6.0 kb. m22 gave the same hybrid-
ization pattern as the 1.1-kb EcoRI subclone of m871 (data not
shown).
The 0.9-kb XhoI-EcoRI fragment of m21 covers part of the
39-UTR of the transcript(s) that encodes dystrobrevin-2. Hy-
bridization of this probe to Northern blots gave a complex band
pattern (Fig. 5C). In brain, this probe hybridizes to transcripts
of 6.0, 4.3, 3.5, 3.3, 1.7, 1.2, 0.8, and 0.7 kb. In skeletal muscle,
heart, and lung, the 0.9-kb XhoI-EcoRI fragment of m21 pre-
dominantly hybridizes to 3.5-kb (3.3-kb in muscle) and 1.7-kb
transcripts. In muscle and lung, this probe also hybridizes
weakly to a 6.0-kb transcript. Additionally, in muscle, a 4.3-kb
transcript can also be detected.
This complex pattern is very similar to the pattern of hybrid-
ization of m872 to the same Northern blots. m872 also contains
part of the dystrobrevin-2 39-UTR as well as the majority of the
coding region. This indicates that the 39-UTR of the brain
dystrobrevin-2 transcript, present in m872, m32, m21, and
m11, cross-hybridizes to several different dystrobrevin-encod-
ing transcripts. This hybridization pattern may be due to a
repetitive element within the 39-UTR or may reflect the num-
ber of dystrobrevin-encoding transcripts that utilize this UTR
or a UTR with a very similar sequence.
Expression of Dystrobrevin Isoforms—Expression of the dys-
trobrevin isoforms was determined by immunoblot analysis.
Two anti-peptide antibodies were made using synthetic pep-
FIG. 4. Alternatively spliced dystrobrevin isoforms. A, the pre-
dicted amino acid sequence of the splice variants at the vr2 site (C). The
sequence encoded by the cDNA clone m871 was compared with the
dystrobrevin-1 (encoded by m24), dystrobrevin-2 (encoded by m32), and
Torpedo 87-kDa protein sequences. The amino acid number of the m871
sequence is not shown because m871 does not contain a complete open
reading frame. The asterisk denotes the stop codon of the dystrobrevin-2
transcript. B, the predicted amino acid sequence of the tissue-specific
splice variants at the vr3 site. The sequences of dystrobrevin-1 (brain)
and the Torpedo 87-kDa protein were compared with the deduced
amino acid sequence of RT-PCR products cloned from skeletal muscle
first strand cDNA. The skeletal muscle sequence is identical to that
obtained from heart cDNA. The sequences of dystrobrevin-1 and dys-
trobrevin-2 at vr1 are also identical. C, diagrammatic representation of
the dystrobrevin isoforms in brain and muscle. hI and hII denote the
location of the a-helices predicted to form the coiled-coils conserved in
proteins with homology to the C terminus of dystrophin (31). vr1, -2,
and -3 are the sites of alternative splicing described in the text. The
locations of the peptides used to produce Ab 308 and Ab 433 and the
syntrophin-binding site are indicated. The N-terminal regions of dys-
trobrevin-3 and dystrobrevin-4 are represented by broken boxes; this
reflects the fact that the N-terminal encoding sequences have not been
determined.
FIG. 5. Northern blot analysis of dystrobrevin transcripts in
mouse tissues. 25 mg of total RNA was hybridized with the following
probes: A, m872 (Fig. 2B); B, 1.1-kb EcoRI fragment of m871 (Fig. 2A);
C, 0.9-kb XhoI-EcoRI fragment of m21 (Fig. 2B). Sizes of the RNA
markers and the ribosomal RNAs are indicated with arrows.
FIG. 3. A, cDNA sequence and conceptual translation of clone m24, encoding dystrobrevin-1. The sequences of the peptides used to produce Ab
308 and Ab 433 are in boldface. B, cDNA sequence and conceptual translation of clone m32, encoding dystrobrevin-2. C, multiple sequence
alignment of dystrobrevin-1 and dystrobrevin-2 with the Torpedo 87-kDa protein. Sequence alignments were prepared using the programs PILEUP
and PRETTYPLOT (Genetics Computer Group Version 7.3 software package).
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tides corresponding to residues 308–328 (Ab 308) and residues
433–451 (Ab 433), both of which should recognize all the dys-
trobrevin isoforms predicted by the cDNA clones and described
herein. Preparations containing the dystrobrevin isoforms
were partially purified from detergent extracts of several tis-
sues by immunoaffinity chromatography using the pan-syntro-
phin mAb 1351, taking advantage of the tight association be-
tween syntrophins and dystrobrevin. Northern blot analysis
shows that the levels of the various dystrobrevin transcripts
are highly variable among tissues. To identify dystrobrevin
isoforms in a wide range of tissues, including those in which the
dystrobrevin expression was expected to be quite low, SDS gel
sample loadings for immunoblots were normalized for equal
amounts of syntrophin (Fig. 6). Immunoblotting with affinity-
purified antibodies revealed a complex pattern of dystrobrevin-
immunoreactive bands depending on the tissue examined. La-
beling was judged to be specific since it was eliminated by
preincubation of the antibody with the corresponding peptide.
As predicted from the cDNA sequence analysis, Ab 308 recog-
nized two bands in skeletal muscle that correspond approxi-
mately in size to dystrobrevin-3 and dystrobrevin-4. Brain ex-
presses two major proteins, presumably dystrobrevin-1 and
dystrobrevin-2, both of which are slightly smaller than their
skeletal muscle counterparts, consistent with the pattern of
alternative splicing described in muscle. The patterns in other
tissues examined are much simpler, with one major dystrobre-
vin isoform predominating.
Immunoblotting with a second antibody, Ab 433, confirmed
the results obtained with Ab 308, but also revealed additional
complexity. A high molecular mass isoform, clearly larger than
the predicted muscle “long” isoform, dystrobrevin-3, was iden-
tified by Ab 433 in skeletal muscle (Fig. 6). Ab 308 and other
dystrobrevin antibodies failed to detect this band, raising the
possibility that this high molecular mass protein may not be a
dystrobrevin isoform. In addition, the major band in liver rec-
ognized by both antibodies appears to be larger than the cor-
responding bands in heart and muscle. Interestingly, in the
intestine, a tissue with a considerable smooth muscle content,
dystrobrevin immunoreactivity was very low in the syntrophin
preparation. Weak and diffuse dystrobrevin immunoreactivity
is also apparent in the kidney. Although the proteins identified
by immunoblotting are largely consistent with the major iso-
forms predicted by cDNA cloning, there appears to be addi-
tional complexity yet to be identified.
Localization of Dystrobrevin Proteins in Skeletal Muscle—
The location of dystrobrevin immunoreactivity in skeletal mus-
cle was examined by immunofluorescence microscopy. In cryo-
sections of rat sternomastoid muscle, Ab 433 labeled the
sarcolemma with particularly strong staining of the NMJs (Fig.
7). A similar labeling pattern was obtained with Ab 308 (data
not shown). This distribution agrees with previous results on
vertebrate skeletal muscle using antibodies against the Tor-
pedo 87-kDa protein (24).
DISCUSSION
This paper describes the isolation and characterization of
cDNA clones encoding isoforms of the murine homologue of the
87-kDa postsynaptic protein originally identified in the electric
organ of Torpedo californica. In contrast to the situation in
Torpedo, where there appears to be a single transcript, in the
mouse, there are multiple transcripts encoding different pro-
tein isoforms. In mouse brain, the “full-length” transcript is 6.0
kb and encodes a protein with a predicted molecular mass of 78
kDa. We have called this protein dystrobrevin-1. In addition to
the dystrobrevin-1 transcript, several other mRNAs can be
detected in brain. One of these transcripts encodes a protein
with a predicted molecular mass of 59 kDa; we have called this
product dystrobrevin-2. The dystrobrevin-1 transcript is most
similar to the Torpedo mRNA because there is significant se-
quence similarity between the 39-UTRs as well as in the coding
sequence.
The major difference between dystrobrevin-1 and dystrobre-
vin-2 is that they have different C termini. Dystrobrevin-2
lacks the proposed tyrosine kinase substrate domain (1) and
may not be a suitable substrate for tyrosine phosphorylation.
However, dystrobrevin-2 may still be phosphorylated on serine
and threonine residues in a similar manner to the Torpedo
87-kDa protein (40). The other major differences between the
dystrobrevin-1 and dystrobrevin-2 transcripts occur in the un-
translated regions. The cDNA clones m32, m24, and m21 all
have different 59-UTRs. The occurrence of several 59-UTRs is
suggestive of independent regulation. Each transcript may be
regulated by a different promoter and may have separate 59-
FIG. 6. Immunoblot analysis of dystrobrevin gene products in
mouse tissues. Dystrobrevin isoforms associated with syntrophin
were purified from Triton X-100 extracts of tissues using mAb
SYN1351. Sample loadings were adjusted so that the amount of syn-
trophin in each lane was approximately equal (upper panel, anti-syn).
Dystrobrevin isoforms were identified with Ab 308 (middle panel) and
Ab 433 (lower panel). The sizes of the molecular mass markers (in
kilodaltons) are indicated.
FIG. 7. Localization of dystrobrevin in rat skeletal muscle.
Regions of the section containing NMJs were identified by labeling with
a-bungarotoxin (A and C). Dystrobrevin distribution was determined by
staining with Ab 433 alone (B). The specificity of this staining was
confirmed by preincubation of Ab 433 with the appropriate peptide (D).
Bar 5 20 mm.
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noncoding regions, but still utilize the same coding regions and
initiator methionine. The rat gene for brain-derived neurotro-
phic factor has a similarly complex organization. Four short
59-noncoding exons can be spliced to a common coding exon and
are each regulated by separate promoters (41). These promot-
ers confer tissue-specific, axotomy- and neuronal activity-
induced expression in transgenic mice (42). It is therefore
possible that several of the dystrobrevin transcripts in the
brain are transcribed in a region-specific manner from different
promoters.
The 6.0-kb transcript is most abundant in adult brain, but is
also expressed at lower levels in skeletal muscle and lung. In
muscle, heart, and lung, two transcripts of 3.3/3.5 and 1.7 kb
predominate. The major dystrobrevin-encoding isoforms in
muscle and heart differ from their brain counterparts and
include an additional 57 amino acids (vr3) preceding the coiled-
coil domain (Fig. 4C). The vr3 sequence is only present in
skeletal and cardiac muscle and thus represents a significant
difference between the products in brain and muscle. In addi-
tion, the vr3 sequence is also present in muscle transcripts that
are predicted to encode proteins with different C termini, i.e.
with C termini identical to those of dystrobrevin-1 and dystro-
brevin-2. We have called these muscle isoforms dystrobrevin-3
and dystrobrevin-4 (Fig. 4C). An important difference between
dystrobrevin expression in mouse and Torpedo is that dystro-
brevin is not expressed in Torpedo heart (1). In mouse heart,
the 3.5- and 1.7-kb dystrobrevin transcripts are expressed at
levels comparable to those in brain and skeletal muscle. This
finding is consistent with our hypothesis that the dystrobrevins
are ligands for dystrophin/utrophin and syntrophin since these
proteins and their transcripts are also abundant in mouse
heart (43).2
In addition to the differences within the noncoding regions
and the major tissue-specific splice variant, vr3, alternative
splicing at two other sites, vr1 and vr2 (Fig. 4C), occurs. vr1 is
an insertion of 3 amino acids, whereas the vr2 splice is a
replacement of 3 amino acids with a stretch of 9 amino acids.
While the function of this splice variation is unknown, it is
noteworthy that an insertion of 8 amino acids into the coding
sequence of neuronally secreted agrin is associated with a
1000-fold stimulation in AChR clustering activity (44, 45).
Several findings have shown that the dystrobrevins are com-
ponents of one or more protein complexes. Our data demon-
strate that multiple isoforms of the mammalian dystrobrevin
are associated with syntrophin (Fig. 6). Because mAb 1351
detects all three forms of syntrophin, it is not known whether
one form of syntrophin is preferentially associated with the
dystrobrevins. It is a distinct possibility that there are other
dystrobrevin isoforms that are not associated with syntrophin,
presumably because they lack the syntrophin-binding domain
and would therefore not be present in the affinity-purified
syntrophin complex. In addition to syntrophin, dystrophin and
utrophin are also present in dystrobrevin-containing protein
complexes (25, 26). In this study, we have not established
whether the dystrobrevins bind directly to dystrophin and utro-
phin or bind via syntrophin. The assembly of complexes con-
taining dystrophin/utrophin, syntrophin, and the dystrobre-
vins is currently being investigated.
Finally, a recent paper by Yoshida et al. (46) describes the
expression cloning of a partial cDNA for A0, a 94-kDa protein
that copurifies with dystrophin and other components of the
DGC including the syntrophin triplet (47, 48). The derived
sequence has high similarity to the Torpedo 87-kDa protein
sequence and is therefore likely to be the rabbit orthologue of
the Torpedo gene. Interestingly, the mAb used to screen the
library detects a 62-kDa protein in addition to the 94-kDa A0
protein on immunoblots of purified DGC from skeletal muscle.
This observation supports our description of two predominant
dystrobrevin isoforms, both of which we have cloned. Both
forms of A0 are components of the DGC (46), and both are
associated with syntrophin (this study).
In conclusion, we have described several isoforms of murine
dystrobrevin. Multiple dystrobrevin isoforms are present in
syntrophin preparations from different tissues. In muscle, anti-
dystrobrevin antibodies label the NMJ and sarcolemma, in
common with other components of the DGC. We predict that
the dystrobrevins will be general ligands for both dystrophin/
utrophin and syntrophin at the NMJ and sarcolemma, but may
have additional roles in nonmuscle tissues.
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